ecancer

Pembrolizumab is better than ipilimumab for advanced melanoma in phase III trial

Prof Antoni Ribas - UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA

27 Apr 2015

BRAF 'behind the scenes' in melanoma: A scientific story of discovery

Prof Richard Marais - Cancer Research UK Manchester Institute, Manchester, UK

19 Mar 2015

Connecting science, practice and patient outcomes: Use of BRAF inhibitors for treating metastatic melanoma in clinical practice

Dr Bart Neyns - Universitair Ziekenhuis Brussels, Brussels, Belgium

19 Mar 2015

Response and resistance with BRAF inhibitors: Mechanisms, markers and unanswered questions

Dr Keith Flaherty - Massachusetts General Hospital Cancer Centre, Boston, USA

19 Mar 2015

ecancermedicalscience editor's choice for February 2015

Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy

3 Mar 2015

The role of health economics in cancer outcomes research

Prof Bengt Jönsson, Stockholm School of Economics, Stockholm, Sweden

6 Jan 2015

Biobanking biological materials and linkage to clinical information

Dr Peter Riegman, Erasmus Medical Center, Rotterdam, The Netherlands

6 Jan 2015

2nd EurocanPlatform translational research course is good for networking

Dr Diana Montezuma, Portuguese Oncology Institute of Porto, Portugal

6 Jan 2015

Reasons to attend the EurocanPlatform translational research course 2015

Dr Wilfried Reichardt, University Medical Center Freiburg, Freiburg, Germany

6 Jan 2015

Immunotherapy of cancer: recent progress and future challenges

Prof Rolf Kiessling, Karolinska Institutet, Stockholm, Sweden

6 Jan 2015

Epigenome deregulation in cancer

Dr Zdenko Herceg, International Agency for Research on Cancer (IARC), Lyon, France

6 Jan 2015

Aims and successes of the 2nd EurocanPlatform project translational research course

Christina von Gertten, Karolinska Institutet, Stockholm, Sweden

6 Jan 2015

More from ecancer